menu
    • menu
    [{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Macleods Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Macleods Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Macleods Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Macleods Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akums Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Bilayer","sponsorNew":"Exemed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Bilayer","sponsorNew":"Mascot Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Mascot Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Amaryl

    Menu

    Amaryl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glenmark Pharmaceuticals

                            India arrow
                            AGGSpend
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glimepiride,Lobeglitazone sulfate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glenmark gets CDSCO Nod to Study Lobeglitazone Sulfate & Glimepiride FDC

                            Details : Glimepiride & lobeglitazone sulfate fixed dose combination is approved for the treatment of patients with type 2 diabetes.

                            Product Name : Lobg G

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 16, 2024

                            Lead Product(s) : Glimepiride,Lobeglitazone sulfate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exemed Pharmaceuticals

                            India arrow
                            AGGSpend
                            Not Confirmed

                            Exemed Pharmaceuticals

                            India arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glimepiride,Empagliflozin,Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exemed gets CDSCO Nod to Study Empagliflozin, Glimepiride & Metformin FDC

                            Details : Empagliflozin, metformin and glimepiride fixed dose combination is being evaluated for the treatment of patients with type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 07, 2024

                            Lead Product(s) : Glimepiride,Empagliflozin,Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mascot Health

                            India arrow
                            AGGSpend
                            Not Confirmed

                            Mascot Health

                            India arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glimepiride,Dapagliflozin,Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mascot Sets New Diabetes Care Standard with DCGI-Approved Dapagliflozin FDC

                            Details : Dapagliflozin, metformin and glimepiride fixed dose combination is approved for the treatment of patients with type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 11, 2023

                            Lead Product(s) : Glimepiride,Dapagliflozin,Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mascot Health

                            India arrow
                            AGGSpend
                            Not Confirmed

                            Mascot Health

                            India arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mascot Health Series gets DCGI Nod for Triple Combination Diabetes Medication

                            Details : Sitagliptin, metformin and glimepiride fixed dose combination is approved for the treatment of patients with type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 07, 2023

                            Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Akums Lifesciences

                            India arrow
                            AGGSpend
                            Not Confirmed

                            Akums Lifesciences

                            India arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glimepiride,Lobeglitazone sulfate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akum gets CDSCO Panel Nod to Manufacture Market Glimepiride Lobeglitazone FDC

                            Details : Glimepiride & lobeglitazone sulfate fixed dose combination is approved for the treatment of patients with type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : Glimepiride,Lobeglitazone sulfate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Macleods Pharmaceuticals Limited

                            India arrow
                            AGGSpend
                            Not Confirmed

                            Macleods Pharmaceuticals Limited

                            India arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Macleod gets CDSCO Nod to Study Sitagliptin, Metformin & Glimepiride FDC

                            Details : Sitagliptin, metformin and glimepiride fixed dose combination is being evaluated for the treatment of patients with type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2022

                            Lead Product(s) : Glimepiride,Metformin,Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            AGGSpend
                            Not Confirmed

                            Sun Pharmaceutical Industries Limited

                            India arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glimepiride,Dapagliflozin Propanediol Monohydrate,Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sun Pharma Dapagliflozin Glimepiride Metformin FDC gets CDSCO Panel Nod for Phase 3 Trial

                            Details : Dapagliflozin, metformin and glimepiride fixed dose combination is approved for the treatment of patients with type 2 diabetes.

                            Product Name : Gemer Dapa

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 24, 2021

                            Lead Product(s) : Glimepiride,Dapagliflozin Propanediol Monohydrate,Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth